Abstract |
Smouldering multiple myeloma (SMM) is associated with increased risk of progression to multiple myeloma within 2 years, with no approved treatments. Elotuzumab has been shown to promote natural killer (NK) cell stimulation and antibody-dependent cellular cytotoxicity (ADCC) in vitro. CD56dim (CD56dim /CD16+ /CD3- /CD45+ ) NK cells represent the primary subset responsible for elotuzumab-induced ADCC. In this phase II, non-randomized study (NCT01441973), patients with SMM received elotuzumab 20 mg/kg intravenously (cycle 1: days 1, 8; monthly thereafter) or 10 mg/kg (cycles 1, 2: weekly; every 2 weeks thereafter). The primary endpoint was the relationship between baseline proportion of bone marrow-derived CD56dim NK cells and maximal M protein reduction; secondary endpoints included overall response rate (ORR) and progression-free survival (PFS). Fifteen patients received 20 mg/kg and 16 received 10 mg/kg; combined data arepresented. At database lock (DBL, September 2014), no association was found between baseline CD56dim NK cell proportion and maximal M protein reduction. With minimum 28 months' follow-up (DBL: January 2016), ORR (90% CI) was 10% (2·7-23·2) and 2-year PFS rate was 69% (52-81%). Upper respiratory tract infections occurred in 18/31 (58%) patients. Four (13%) patients experienced infusion reactions, all grade 1-2. Elotuzumab plus lenalidomide/ dexamethasone is under investigation for SMM.
|
Authors | Sundar Jagannath, Jacob Laubach, Ellice Wong, Keith Stockerl-Goldstein, Cara Rosenbaum, Madhav Dhodapkar, Ying-Ming Jou, Mark Lynch, Michael Robbins, Suresh Shelat, Kenneth C Anderson, Paul G Richardson |
Journal | British journal of haematology
(Br J Haematol)
Vol. 182
Issue 4
Pg. 495-503
(08 2018)
ISSN: 1365-2141 [Electronic] England |
PMID | 29808907
(Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, N.I.H., Extramural)
|
Copyright | © 2018 The Authors. British Journal of Haematology published by John Wiley & Sons Ltd. |
Chemical References |
- Antibodies, Monoclonal, Humanized
- Antigens, CD
- Neoplasm Proteins
- elotuzumab
- Dexamethasone
- Lenalidomide
|
Topics |
- Adult
- Aged
- Antibodies, Monoclonal, Humanized
(administration & dosage, adverse effects)
- Antibody-Dependent Cell Cytotoxicity
(drug effects)
- Antigens, CD
(blood, immunology)
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage, adverse effects)
- Dexamethasone
(administration & dosage, adverse effects)
- Disease-Free Survival
- Female
- Humans
- Killer Cells, Natural
(immunology, metabolism)
- Lenalidomide
(administration & dosage, adverse effects)
- Male
- Middle Aged
- Neoplasm Proteins
(blood, immunology)
- Smoldering Multiple Myeloma
(blood, drug therapy, immunology, mortality)
- Survival Rate
|